Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of KL001 in Severe Hemophilia B
NCT06119659Phase 1Unknown
- Sponsor
- Zhejiang University
- Start
- Nov 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of KL001 in hemophilia B (HB) (3 arms), sponsored by Zhejiang University. Primary endpoints: Incidence of treatment-related adverse events at 52 weeks, Antibody against KL001 AAV vector capsid protein at 52 weeks and 1 more. Status: unknown.
02
Drugs
KL001
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT06119659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06119659.